Liminatus Pharma, Inc. is a pre clinical stage biopharmaceutical company focused on developing a novel cancer therapy that exploits the immune system. The company’s sole product candidate is a humanized anti CD47 monoclonal antibody (designated IBA101) intended to block the CD47 “don’t eat me” signal on tumor cells and promote macrophage mediated phagocytosis. Unlike first generation CD47 inhibitors, IBA101 is engineered to bind preferentially to immune cells while sparing red blood cells and platelets, thereby avoiding the anemia and thrombocytopenia seen with earlier agents. Pre clinical work has included chemistry manufacturing and controls development, toxicology studies in non human primates, and efficacy demonstrations in mouse tumor models where the antibody showed strong activity when combined with PD1/PDL1 blockade. The data support the preparation of an investigational new drug application and a planned phase 1 trial in South Korea focusing on non small cell lung cancer patients. The company intends to advance the antibody through clinical development and eventually seek regulatory approval for use in oncology.
Liminatus Pharma, Inc. currently has no commercial product and therefore generates no revenue from product sales. The company expects future revenue to arise from the sale of its antibody, either as a monotherapy or in combination with approved immune checkpoint inhibitors such as PD1/PDL1 blockers, and from potential licensing or partnership agreements with larger pharmaceutical firms. Revenue could also be generated through milestone payments, royalty streams, and co promotion fees once a product reaches market. Until a product reaches the market, the firm relies on external financing, including proceeds from public offerings and strategic investments, to fund its research and development activities. The company has disclosed that it raised approximately $3.46 million in a recent best efforts offering to support ongoing preclinical and early clinical work.
Within the immuno oncology landscape, Liminatus Pharma, Inc. positions itself as a developer of a next generation CD47 inhibitor that seeks to overcome the safety limitations of earlier molecules such as magrolimab. The company’s antibody has demonstrated in preclinical studies a lack of binding to red blood cells and platelets, a differentiation that could allow broader use in combination regimens. Major competitors in the checkpoint inhibitor space include Merck & Co., Roche (through Genentech), Bristol Myers Squibb, AstraZeneca, and Pfizer, all of which market established PD1/PDL1 therapies and are actively pursuing their own CD47 programs. In addition to these large pharma players, several biotechnology firms are advancing CD47 targeting molecules, though many have faced clinical setbacks due to hematologic toxicity. The global market for PD1/PDL1 blockade was estimated at $49.5 billion in 2023 and is projected to reach $123.3 billion by 2033, providing a substantial opportunity for complementary agents. Liminatus believes its engineered Fc region reduces hematologic toxicity while preserving potent anti tumor activity, potentially enabling smoother clinical development and a stronger value proposition for combination therapies. The company also notes that its antibody has shown synergistic activity in preclinical models when paired with PD1/PDL1, LAG 3, TIGIT, and other checkpoint inhibitors, highlighting its versatility in immuno oncology regimens.
Although Liminatus Pharma, Inc. does not yet have an approved product, its anticipated customers will be hospitals, oncology clinics, and treatment centers that administer immunotherapy to patients with solid cancers, especially those with non small cell lung cancer. The company also expects to engage with biopharmaceutical partners that may co develop or combine its antibody with existing PD1/PDL1 agents, thereby reaching physicians who prescribe those regimens. Ultimately, the end users are patients receiving cancer treatment who would benefit from a therapy that enhances macrophage mediated tumor clearance without causing significant blood related side effects. In addition, the company sees potential applications beyond oncology, such as in the treatment of chronic inflammatory conditions where macrophage activation could help clear senescent cells and reduce tissue damage, potentially broadening the customer base to include specialists in cardiology, metabolic disease, and neurology.